Cell-based therapy is considered to be a promising therapeutic strategy for stroke treatment. Although unfractionated bone marrow mononuclear cells (BMMNCs) have been tried in both preclinical and clinical trials, the effective subpopulations need to be identified. In this study, we used fluorescence-activated cell sorting to harvest the CXCR4 Taken together, our study shows for the first time that the CXCR4 + CD45 À BMMNC subpopulation is superior to unfractionated BMMNCs in ameliorating cerebral damage in a mouse model of tMCAO and could represent a new therapeutic approach for stroke treatment.
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Introduction
Cell transplantation-based regenerative therapy provides us with a promising approach for stroke treatment (Bliss et al., 2010; Burns and Steinberg, 2011; Liu et al., 2014a; Misra et al., 2012) . Compared with other cell sources, bone marrow mononuclear cells (BMMNCs) have attracted the interest of many researchers because their use avoids ethical concerns, and they are easy to obtain and purify. They can be harvested allogeneically or autologously from bone marrow within hours, no cell culture procedures are needed, and they can be administered immediately into the recipient through various routes. Over the past decade, evidence from preclinical studies has shown that grafting BMMNCs after cerebral ischemia provides substantial therapeutic effects (Boltze et al., 2011; Fujita et al., 2010; Hess and Hill, 2011; Mendez-Otero et al., 2007; Prasad et al., 2012) . Despite progress in this field, the detailed mechanism through which BMMNCs exert their protective effects in cerebral ischemia remains elusive.
BMMNCs harbor a heterogeneous population that contains mature and immature cells in the myeloid and lymphoid lineages, such as mesenchymal stem cells (MSCs), hematopoietic stem cells http://dx.doi.org/10.1016/j.bbi.2014.12.015 0889-1591/Ó 2014 Elsevier Inc. All rights reserved.
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